Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

Nano-X Imaging Ltd
NASDAQ:NNOX

Watchlist Manager
Nano-X Imaging Ltd Logo
Nano-X Imaging Ltd
NASDAQ:NNOX
Watchlist
Price: 2.31 USD 7.94% Market Closed
Market Cap: $147.4m
Write Note Create Alert Ask AI

Nano-X Imaging Ltd
Investor Relations

Nano-X Imaging Ltd. engages in the development of medical imaging systems.

Show more
Loading
NNOX
S&P 500
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 20, 2025
AI Summary
Q3 2025

Revenue Growth: Nanox reported Q3 2025 revenue of $3.4 million, up from $3.0 million in Q3 2024, with growth driven mainly by teleradiology services.

2026 Guidance: Management reiterated 2026 revenue guidance of more than $35 million, expecting growth to ramp up through the year with a significant ramp in the latter quarters.

Strategic Acquisitions: The acquisition of Vaso Healthcare IT was completed, expanding Nanox's U.S. customer base and bringing in approximately $4 million in annual revenue.

AI Momentum: Nanox emphasized a strategic shift to integrate AI, highlighting new partnerships and expanding clinical trials—especially for lung cancer screening.

Operational Efficiency: The company is focusing on lean operations and expects the AI segment to reach EBITDA breakeven in 2026, with the broader business targeted for 2027.

European Expansion: New distribution agreements in the Czech Republic and France are strengthening Nanox’s presence in Europe.

Product Launch: The next-generation AI-ready Nanox.ARC X system is set to launch at RSNA, aiming to accelerate market penetration.

Key Financials
Revenue
$3.4 million
Net Loss
$13.7 million
Gross Loss
$2.9 million
Teleradiology Revenue
$3.1 million
Teleradiology Gross Profit
$0.2 million
Teleradiology Gross Margin
25%
Revenue from Imaging Systems and OEM Services
$175,000
AI Solution Revenue
$0.1 million
AI Solution Gross Loss
$1.9 million
Research and Development Expenses
$4.6 million
Sales and Marketing Expenses
$1.5 million
General and Administrative Expenses
$5.3 million
Cash, Cash Equivalents, and Marketable Securities
$55.5 million
Short-term Loans from Bank
$3.2 million
Shares Outstanding
65.4 million
Vaso Healthcare IT Revenue Contribution (estimated)
$4 million
Earnings Call Recording
Open Full Analysis Open Transcript
Other Earnings Calls

Management

Mr. Erez I. Meltzer
CEO & Acting Chairman of the Board
No Bio Available
Mr. Ran Daniel
Chief Financial Officer
No Bio Available
Ms. Tamar Aharon Cohen
Executive VP, Chief Marketing Officer and Head of the Sales & Marketing
No Bio Available
Mr. James M. Dara
GM of Source & Services Division and Head of Nanox USA
No Bio Available
Mr. Ofir Koren
General Manager of Nanox.ARC Division
No Bio Available
Ms. Marina Gofman Feler
Chief Legal Officer
No Bio Available
Dr. Orit Wimpfheimer M.D.
Chief Medical Officer & VP of Product Nanox AI
No Bio Available
Ms. Gali Yahav Attias
Chief of Corporate Resources
No Bio Available
Noga Shabshin
Head of Tomosynthesis of ARC Division
No Bio Available
Sharon Saban
VP of R&D and C.O.O. of AI Division
No Bio Available

Contacts

Address
Neve Ilan
Communications Center
Contacts
+972025476333.0
www.nanox.vision
sparklesyt

See Also

Summary
NNOX intrinsic value, competitors valuation, and company profile.
DCF Valuation
NNOX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NNOX stock valuation using valuation multiples.
Wall Street Estimates
NNOX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NNOX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Back to Top
ALPHA SPREAD
Follow us
Join more than 317,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.